Frequent requirement of hedgehog signaling in non-small cell lung carcinoma von Yuan, Z, Goetz, J A, Singh, S, Ogden, S K, Petty, W J, Black, C C, Memoli, V A, Dmitrovsky, E, Robbins, D J

Volltext

Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer von Chang, Antao, Liu, Liang, Ashby, Justin M, Wu, Dan, Chen, Yanan, O'Neill, Stacey S, Huang, Shan, Wang, Juan, Wang, Guanwen, Cheng, Dongmei, Tan, Xiaoming, Petty, W J, Pasche, Boris C, Xiang, Rong, Zhang, Wei, Sun, Peiqing

Volltext

Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? von Yang, M., Forbes, M.E., Bitting, R.L., O'Neill, S.S., Chou, P -C, Topaloglu, U., Miller, L.D., Hawkins, G.A., Grant, S.C., DeYoung, B.R., Petty, W.J., Chen, K., Pasche, B.C., Zhang, W.

Volltext

Retinoid target genes in acute promyelocytic leukemia von PITHA-ROWE, I, PETTY, W. J, KITAREEWAN, S, DMITRNVSKY, E

Volltext

Abstract PO-009: Rural/urban and race differences in factors related to cessation readiness among cigarette smokers presenting for lung cancer screening in community settings von Weaver, Kathryn E., Sutfin, Erin L., Dressler, Emily, Bellinger, Christina, Miller, David P., Chiles, Caroline, Petty, W. J., Lesser, Glenn, Foley, Kristie L.

Volltext

Severe neurologic complications of immune checkpoint inhibitors: a single-center review von Mancone, Sarah, Lycan, Thomas, Ahmed, Tamjeed, Topaloglu, Umit, Dothard, Andrew, Petty, William J., Strowd, Roy E.

Volltext

C71 THORACIC CANCER: PATHOGENESIS, PREVENTION, AND TREATMENT: Growing A Thoracic Oncology Program von Bellinger, C R, Hovda, J, Petty, W J, Ruiz, J, Dotson, T L, Wudel, L J

Volltext

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas von Petty, W Jeffrey, Aklilu, Mebea, Varela, Victor A, Lovato, James, Savage, Paul D, Miller, Antonius A

Volltext

Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC von Waller, L. L., Miller, A. A., Streer, N. P., Lovato, J. F., Petty, W. J.

Volltext

Ethical Attitudes in Small Businesses and Large Corporations: Theory and Empirical Findings from a Tracking Study Spanning Three Decades von Longenecker, Justin G., Moore, Carlos W., Petty, J. William, Palich, Leslie E., Mckinney, Joseph A.

Volltext

Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues von Ruiz, J., Chou, J., Geisinger, K. R., Schoppe, C. H., Miller, A. A., Willingham, M. C., Petty, W. J., Bolemon, B. H., Miller, L. D.

Volltext

Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT)... von Stinchcombe, T., Socinski, M. A., Moore, D. T., Gettinger, S. N., Decker, R. H., Petty, W. J., Blackstock, A. W., Schwartz, G., Lankford, S., Morris, D. E.

Volltext

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers von PETTY, W. Jeffrey, DRAGNEV, Konstantin H, IWATA, Kenneth K, RIGAS, James R, DMITROVSKY, Ethan, MEMOLI, Vincent A, YAN MA, DESAI, Neil B, BIDDLE, Adrian, DAVIS, Thomas H, NUGENT, William C, MEMOLI, Natalie, HAMILTON, Marta

Volltext

A Novel Retinoic Acid Receptor β Isoform and Retinoid Resistance in Lung Carcinogenesis von Petty, W. Jeffrey, Li, Na, Biddle, Adrian, Bounds, Rebecca, Nitkin, Christopher, Ma, Yan, Dragnev, Konstantin H., Freemantle, Sarah J., Dmitrovsky, Ethan

Volltext

Bexarotene and Erlotinib for Aerodigestive Tract Cancer von DRAGNEV, Konstantin H, PETTY, W. Jeffrey, SHAH, Sumit, BIDDLE, Adrian, DESAI, Neil B, MEMOLI, Vincent, RIGAS, James R, DMITROVSKY, Ethan

Volltext

Phase I trial of angiotensin-(1–7): An endogenous anti-angiogenic hormone von Petty, W. J., Miller, A. A., McCoy, T. P., Gallagher, P. E., Tallant, E. A., Torti, F. M.

Volltext

Expression of cyclin D3 confers resistance to erlotinib von Petty, W. J., Voelzke, W. R., Memoli, V. A., Dragnev, K. H., Urbanic, J. J., Rigas, J. R., Dmitrovsky, E.

Volltext

Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-s... von Socinski, M. A., Stinchcombe, T. E., Halle, J. S., Moore, D. T., Petty, W. J., Blackstock, A. W., Gettinger, S. N., Decker, R. H., Khandani, A. H., Morris, D. E.

Volltext

Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small... von Socinski, M. A., Morris, D. E., Stinchcombe, T. E., Halle, J. S., Moore, D. T., Tynan, M. T., Siegel, M. A., Petty, W. J., Blackstock, A. W., Khandani, A. H., Rosenman, J. G.

Volltext

Cyclin D1 as a target for chemoprevention von Petty, W.Jeffrey, Dragnev, Konstantin H., Dmitrovsky, Ethan

Volltext